Echo IQ (EIQ) Life Sciences Virtual Investor Forum 2025 summary

Business and financial overview

• Strong balance sheet with $15M in cash, no debt, and a 12–18 month runway at a $600–700K monthly burn rate.

• Valuation stands at $145–150M, with expectations of meaningful revenue growth in upcoming quarters.

• Commercialization mode initiated, with a focus on expanding hospital integrations and a SaaS subscription model.

• Revenue guidance and significant milestones expected in early 2026, including FDA clearance for heart failure solution.

• Well-funded for current operations, with future capital raises likely tied to IPO plans.

Technology and product development

• AI-driven neural network analyzes echocardiogram measurements to diagnose aortic stenosis and heart failure.

• Technology delivers real-time phenotypic risk scores, improving diagnostic accuracy, especially for women.

• Achieved 100% accuracy in diagnosing severe aortic stenosis in clinical trials; heart failure model validated at 99.5% sensitivity and 91% specificity.

• FDA clearance for aortic stenosis solution obtained in late 2024; heart failure solution submission underway with anticipated clearance in early 2026.

• Access to the National Echo Database of Australia enables robust model training and future product pipeline.

Commercialization and market strategy

• Integrated at flagship sites like Beth Israel Deaconess and six other hospitals, with 40–50 more in late-stage pipeline.

• Subscription model leverages existing and upcoming reimbursement codes, with anticipated inflection in 2026.

• Contract sales team covers 70% of the U.S.; building out direct sales force and strategic partnerships for rapid expansion.

• Targeting large teaching institutions, hospital-based clinics, and cardiologist-owned practices.

• KPIs to be reported in 2026, including number of integrations, echocardiograms processed, and revenue.